AJANTPHARM2024-04-012024-06-30 AJANTPHARM2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2024-06-30 AJANTPHARM2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532331 AJANTPHARM NOTLISTED Ajanta Pharma Limited Equity 2024-04-01 2025-03-31 2024-07-30 2024-07-17 INR Crores First quarter 13:30:00 14:55:00 2024-07-30 2024-07-30 Not applicable Single segment PHARMACEUTICAL 2024-04-01 2024-06-30 Unaudited Standalone 10772700000.00 283700000.00 11056400000.00 2384100000.00 446100000.00 -250800000.00 2656800000.00 7200000.00 329200000.00 2378200000.00 7950800000.00 3105600000.00 0.00 3105600000.00 714200000.00 31100000.00 745300000.00 0.00 2360300000.00 0.00 0.00 0.00 0.00 2360300000.00 -24300000.00 2336000000.00 2336000000.00 0.00 250700000.00 2 18.77 18.75 0.00 0.00 18.77 18.75 1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2024. The statutory auditors have expressed an unmodified opinion. The review report has been filed with the stock exchange and is available on the company’s website. 2. The figures for the quarter ended 31 March 2024 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter ended 31 December 2023. 3. Other income includes: Quarter ended Year ended (Rs. in Crores) 30-Jun-24 31-Mar-24 30-Jun-23 31-Mar-24 Dividend from subsidiaries (in other income) - - - 29.13 Foreign exchange gain (in other income) 10.83 18.27 19.68 43.16 Foreign exchange loss (in other expense) - - 6.97 - 4. During the quarter 1,000 (previous year 1,000) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs. 2,000 (previous year Rs. 2,000) and securities premium by Rs. 0.18 crores (previous year Rs. 0.18 crores). 5. On 2 May 2024, Company has announced buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity share capital at Rs. 2,770 per equity share for an aggregate amount of Rs. 285.00 crores. The buyback opened on 05 June 2024, closed on 11 June 2024 and Company extinguished those shares on 27 June 2024. 6. The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals . 7. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. Other Expenses 2378200000.00 Amount of items that will not be reclassified to profit and loss -37400000.00 -37400000.00 -13100000.00 0.00